Journal
SEMINARS IN CANCER BIOLOGY
Volume 19, Issue 5, Pages 338-343Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2009.05.001
Keywords
Growth factor; Angiogenesis; Drug resistance; Cancer; Metastasis
Categories
Funding
- Swedish Research Council
- Swedish Heart and Lung Foundation
- Swedish Cancer Foundation
- Karcilinska Institute fund
- Karolinska Gender foundation
- Soderberg Foundation
- European Union [504743]
- European VascuPlug [STRP 013811]
Ask authors/readers for more resources
Several antiangiogenic agents, including bevacizumab, sunitinib, and sorafenib, which mainly target the VEGF signaling system, have been approved for the treatment of human cancers. These drugs have been paired with conventional chemotherapeutic agents to treat different types of cancers, including colorectal and lung cancers; however, the patient response rate and resultant increase in overall survival time have been rather modest. The current antiangiogenic regimen is far from optimal. Improvements of therapeutic efficacy and minimization of adverse effects and drug resistance are urgent tasks that are most likely to be resolved by understanding the molecular mechanisms underlying tumor angiogenesis. The aim of this article is to discuss these clinically related issues, to highlight several recent examples of the complex interplays between tumor-produced angiogenic factors, and to propose a new paradigm for improvement of therapeutic intervention of tumor angiogenesis. (C) 2009 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available